Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edesa Biotech, Inc. (Nasdaq: EDSA) SEC filings page compiles the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on immuno-inflammatory diseases, Edesa uses its SEC reports to provide detail on clinical programs, funding agreements and capital markets activity related to its Medical Dermatology and Respiratory pipelines.
Investors can review current reports on Form 8-K that discuss material events such as positive Phase 3 results for paridiprubart (EB05) in Acute Respiratory Distress Syndrome (ARDS), amendments to a multi-year contribution agreement with the Government of Canada’s Strategic Innovation Fund, and updates to at-the-market equity offering programs. Other 8-K filings reference earnings releases for fiscal periods, giving context on operating expenses, research and development spending, and cash resources supporting programs like EB06 for vitiligo and EB01 for Allergic Contact Dermatitis.
Through its shelf registration statements and prospectus supplements, Edesa documents how it raises capital via at-the-market offerings and private placements of preferred and common shares. These filings outline the structure and size of offerings, use of proceeds for advancing EB06 into Phase 2 studies, and the terms under which additional common shares may be issued. Contribution agreements and amendments filed or referenced in periodic reports describe partially repayable government funding for EB05 clinical trials, regulatory submissions and non-clinical safety studies.
On Stock Titan, users can access Edesa’s SEC filings as they are made available from EDGAR and benefit from AI-powered summaries that highlight the key points in lengthy documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q) and material 8-Ks. These tools help clarify disclosures on clinical milestones, financial obligations, government funding arrangements and equity issuance, and can also surface insider and governance-related filings such as Forms 3, 4 and 5 when they are filed. This page is a resource for analyzing how Edesa reports its progress, risks and capital structure in connection with its dermatology and respiratory drug candidates.
Edesa Biotech, Inc. filed a current report to disclose that on December 12, 2025 it issued a press release announcing its financial results for the fiscal year ended September 30, 2025. The press release is included as Exhibit 99.1 and is furnished, rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced.
Edesa Biotech (EDSA) reported an insider transaction by CEO, Director and 10% Owner Pardeep Nijhawan. On 11/03/2025, he acquired 6,968 common shares via a grant of restricted share units that vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan at a reported price of $0.
Following the transaction, the reporting person beneficially owned 482,612 shares directly. He also reported indirect holdings of 341,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 shares held by The New Nijhawan Family Trust 2015, 32,013 shares held by The Digestive Health Clinic Inc., and 53,104 shares held by 1968160 Ontario Inc.
Edesa Biotech (EDSA) reported positive Phase 3 results for paridiprubart (EB05) in ARDS, stating the study met primary and secondary endpoints with statistical significance. In the intention-to-treat population (n=104), 28-day mortality was 39% with paridiprubart plus standard of care versus 52% with placebo, an absolute survival improvement of 13% and a 25% relative risk reduction (p<0.001). A survival benefit persisted at 60 days: 46% vs 59%, a 13% absolute improvement and 22% relative risk reduction (p=0.003).
The company also reported fewer patients required invasive mechanical ventilation, with a 41% higher relative rate of clinical improvement at Day 28. In a safety population of more than 275 subjects across Phase 2/3, EB05 was generally well-tolerated. Patients were enrolled at 38 hospitals in the U.S., Canada and Colombia. The program is supported by the U.S. government’s “Just Breathe” study and Canada’s Strategic Innovation Fund. Enrollment was discontinued early for business reasons, and efficacy analyses used multivariate logistic regression with prespecified adjustments.
Pardeep Nijhawan, Chief Executive Officer, Director and reported >10% owner of Edesa Biotech, Inc. (EDSA), received a grant of 5,908 restricted share units that vested in full upon grant on 10/02/2025 under the company's 2019 Equity Incentive Compensation Plan. The filing shows 475,644 common shares beneficially owned following the transaction, with 341,702 shares held indirectly by Pardeep Nijhawan Medicine Professional Corporation and additional indirect holdings through related entities and a family trust totaling 118,726 shares. The filing includes standard disclaimers that the reporting person disclaims beneficial ownership of certain indirect holdings except to the extent of pecuniary interest. The form was signed by an attorney-in-fact on 10/03/2025.
Edesa Biotech, Inc. has amended its multi-year contribution agreement with the Government of Canada covering up to CAD $23 million in partially repayable funding for its experimental ARDS drug EB05 (paridiprubart). The amendment shifts the clinical focus from Covid-19–induced Acute Respiratory Distress Syndrome to general ARDS and aligns with participation in a fully funded U.S. government platform study of host-directed therapeutics that includes EB05. The project completion date is extended to December 31, 2028, and the agreement’s expiration moves to the later of December 31, 2045 or the date of last repayment, unless terminated earlier. The repayment schedule is also revised so that the first annual repayment would be due in 2032, and only if the company earns gross revenue, while other terms of the agreement remain in effect.
Edesa Biotech, Inc. filed an 8-K to report that it has filed a new prospectus supplement supporting its at-the-market offering program for the offer and sale of up to $4,006,544 of common shares through H.C. Wainwright & Co. as sales agent. This program operates under an existing At the Market Offering Agreement originally dated October 4, 2024.
The company has previously sold an aggregate of $837,134 of common shares under that agreement and an earlier prospectus supplement tied to a prior Form S-3 registration. The new prospectus supplement and base prospectus form part of a shelf registration statement on Form S-3 that was declared effective by the SEC on September 9, 2025, and a related legal opinion on the validity of the common shares is filed as an exhibit.
Edesa Biotech, Inc. prospectus supplement for debt securities highlights numerous standard biotech risks and detailed outstanding and potential share issuances that could affect shareholders. The filing lists categories of risks including funding availability, clinical trial timing and results, regulatory approvals, competition, intellectual property protection, Nasdaq listing compliance and reliance on key personnel. It discloses a cash-related figure of $4,006,544 and specific share counts: 378,235 options (weighted average exercise $24.71), 137,936 fully vested RSUs, 1,124,171 unvested RSUs, 680,846 shares available under the equity plan, 435,414 Series A-1 convertible preferred, 4,343,750 Series B-1 convertible preferred and 934,590 warrants (weighted average exercise $15.35). The supplement references prior SEC filings including the Annual Report for the year ended September 30, 2024 and several 10-Qs and 8-Ks. Contact for investor relations is provided in Markham, Ontario.
Edesa Biotech, Inc. reported a strengthened liquidity position driven by private placements: cash and cash equivalents increased to $12.36 million at June 30, 2025 and working capital was approximately $12.1 million. For the nine months ended June 30, 2025 the company recorded a net loss of $4.96 million, contributing to an accumulated deficit of $63.65 million. The company received gross proceeds of about $15.0 million from a Series B-1 private placement and $1.54 million from a Series A-1 issuance.
The company continues clinical development across two programs: EB05 is participating in a BARDA-funded platform trial and EB06 is advancing toward a Phase 2 vitiligo study with manufacturing preparation underway. The Canadian Strategic Innovation Fund committed up to C$23 million (partially repayable) to support Phase 3 and related activities. Management states a going concern material uncertainty exists and further financing or strategic activities will be required to fund development beyond current expectations.
Edesa Biotech announced its financial results for the three- and nine-month periods ended June 30, 2025 via a press release that is attached to this Form 8-K as Exhibit 99.1. The filing expressly states the Earnings Release is furnished and shall not be deemed "filed" under the Exchange Act, so it is not subject to Section 18 liabilities and is not incorporated by reference in other filings unless specifically cited. This 8-K itself does not include financial figures or operational details.
On 08/04/2025, Edesa Biotech (EDSA) filed a Form 4 disclosing that CEO, Director and 10% owner Pardeep Nijhawan acquired 6,802 common shares on 08/01/2025. The shares were issued as restricted share units that vested immediately at a cost basis of $0 under the company’s 2019 Equity Incentive Compensation Plan.
Following the grant, Nijhawan’s direct holdings rose to 463,755 shares. He also reports 459,428 shares held indirectly through affiliated entities and a family trust: 341,702 by Pardeep Nijhawan Medicine Professional Corp., 53,104 by 1968160 Ontario Inc., 32,013 by The Digestive Health Clinic Inc., and 32,609 by The New Nijhawan Family Trust 2015. No derivative securities or dispositions were reported.
The filing reflects a routine equity award that slightly increases insider ownership and further aligns the CEO’s economic interests with those of common shareholders; it does not signal any immediate strategic or financial shift.